



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 104 297 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**INID code(s) 72**
- (48) Corrigendum issued on:  
**03.05.2006 Bulletin 2006/18**
- (45) Date of publication and mention  
of the grant of the patent:  
**11.01.2006 Bulletin 2006/02**
- (21) Application number: **99937222.0**
- (22) Date of filing: **08.07.1999**
- (51) Int Cl.:  
**A61K 31/40** <sup>(2006.01)</sup> **A61K 31/35** <sup>(2006.01)</sup>  
**A61P 35/02** <sup>(2006.01)</sup>
- (86) International application number:  
**PCT/US1999/015501**
- (87) International publication number:  
**WO 2000/002555 (20.01.2000 Gazette 2000/03)**

- (54) **COMPOSITIONS FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA**  
ZUSAMMENSETZUNGEN ZUR BEHANDLUNG CHRONISCHER LYMPHATISCHER LEUKÄMIE  
COMPOSITIONS POUR LE TRAITEMENT DE LA LEUCEMIE LYMPHOCITAIRE CHRONIQUE

- |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>(84) Designated Contracting States:<br/><b>AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU<br/>MC NL PT SE</b></p> <p>(30) Priority: <b>09.07.1998 US 92466 P</b><br/><b>29.07.1998 US 94878 P</b></p> <p>(43) Date of publication of application:<br/><b>06.06.2001 Bulletin 2001/23</b></p> <p>(60) Divisional application:<br/><b>06000432.2</b><br/><b>06075053.6</b></p> <p>(73) Proprietor: <b>CEPHALON, INC.</b><br/><b>Frazer, PA 19355 (US)</b></p> <p>(72) Inventor: <b>Nardella, Francis A.</b><br/><b>Scottsdale, AZ 85258 (US)</b></p> <p>(74) Representative: <b>Bizley, Richard Edward et al</b><br/><b>HLBBshaw</b><br/><b>Merlin House</b><br/><b>Falconry Court</b><br/><b>Baker's Lane</b><br/><b>Epping, Essex CM16 5DQ (GB)</b></p> | <p>(56) References cited:<br/><b>US-A- 4 686 213</b> <b>US-A- 5 776 967</b></p> <ul style="list-style-type: none"><li>• <b>NARDELLA FRANCIS A ET AL: "Enhanced clearance of leukemic lymphocytes in B cell chronic lymphocytic leukemia (CLL) with etodolac." ARTHRITIS &amp; RHEUMATISM, vol. 42, no. 9 SUPPL., 1999, page S56 XP008009568 63rd Annual Scientific Meeting of the American College of Rheumatology and the 34th Annual Scientific Meeting of the Association of Rheumatology Health Professionals; Boston, Massachusetts, USA; November 13-17, 1999 ISSN: 0004-3591</b></li><li>• <b>RILEY T N ET AL: "NEW DRUGS A SIX MONTH REVIEW" U S PHARMACIST, vol. 16, no. 9, 1991, pages 34-40, 42, 44, 46, 48-50, 52, 57-58, 60,, XP008009569 ISSN: 0148-4818</b></li></ul> |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).